Impact of chronic outward force on arterial responses of proximal and distal of long superficial femoral artery stent

Hu, Li; Rha, Seung Woon; Choi, Byoung Geol; Choi, Se Yeon; Moon, Sang Ki; Jang, Woo Young; Kim, Woohyeun; Ahn, Jiyun; Park, Sang Ho; Choi, Woong; Rui, Yang; Bai, Wen Wei; Choi, Cheol Ung; Ryu, Yang Gi; Baek, Man Jong; Oh, Dong Joo

doi:10.1186/s12872-021-02141-z

Cited by 6 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study group, the stentto-artery diameter ratio was significantly higher in the distal stent than in the proximal stent (1.55 ± 0.25 vs. 1.3 ± 0.2, p = 0.001). Similarly, the risk of ISR was significantly higher in the distal stent than in the proximal stent (52.6% vs. 37.3%, p = 0.029) [164].…”

Section: Technical and Mechanical Factorsmentioning

confidence: 88%

Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes

Jakubiak

Pawlas

Cieślar

et al. 2021

IJERPH

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a strong risk factor for the development of cardiovascular diseases such as coronary heart disease, cerebrovascular disease, and peripheral arterial disease (PAD). In the population of people living with DM, PAD is characterised by multi-level atherosclerotic lesions as well as greater involvement of the arteries below the knee. DM is also a factor that significantly increases the risk of lower limb amputation. Percutaneous balloon angioplasty with or without stent implantation is an important method of the treatment for atherosclerotic cardiovascular diseases, but restenosis is a factor limiting its long-term effectiveness. The pathogenesis of atherosclerosis in the course of DM differs slightly from that in the general population. In the population of people living with DM, more attention is drawn to such factors as inflammation, endothelial dysfunction, platelet dysfunction, blood rheological properties, hypercoagulability, and additional factors stimulating vascular smooth muscle cell proliferation. DM is a risk factor for restenosis. The purpose of this paper is to provide a review of the literature and to present the most important information on the current state of knowledge on mechanisms and the clinical significance of restenosis and in-stent restenosis in patients with DM, especially in association with the endovascular treatment of PAD. The role of such processes as inflammation, neointimal hyperplasia and neoatherosclerosis, allergy, resistance to antimitotic drugs used for coating stents and balloons, genetic factors, and technical and mechanical factors are discussed. The information on restenosis collected in this publication may be helpful in planning further research in this field, which may contribute to the formulation of more and more precise recommendations for the clinical practice.

show abstract

Section: Technical and Mechanical Factorsmentioning

confidence: 88%

Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes

Jakubiak

Pawlas

Cieślar

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

Preoperative Sizing to Lower In-Stent Restenosis in Peripheral Arterial Occlusive Disease

Jeshari,

Die Loucou,

Leboffe

et al. 2024

Annals of Vascular Surgery

View full text Add to dashboard Cite

Safety and efficacy of drug-eluting stents versus heparin-bonded stents in treatment of femoropopliteal peripheral artery disease: study protocol for a multicentre, prospective randomised controlled trial in China (ELITE trial)

Qi,

Zhang,

Zhao

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionEndovascular therapy has emerged as a prominent strategy for managing femoropopliteal peripheral artery disease, offering acceptable safety and efficacy compared with open surgical bypass. Both paclitaxel-eluting stents and heparin-bonded covered stents have exhibited enhanced clinical outcomes compared with bare metal stents. However, there is currently a lack of level I evidence comparing the safety and efficacy of paclitaxel-eluting stents and heparin-bonded covered stents. Therefore, the primary objective of this study is to systematically evaluate the efficacy and safety outcomes of these two types of stents.Methods and analysisThe ELITE trial is a prospective, multicentre, parallel, randomised controlled trial. A total of 450 patients will be recruited. The primary endpoints of the study include primary patency at 1 year post-index procedure.Ethics and disseminationEthical approval for this study was obtained from the Ethics Committee of West China Hospital of Sichuan University (approval number: 2023–1186). The results will be submitted to a major clinical journal for peer review and publication.Trial registrationELITE trial was registered on 27 September 2023 in the Chinese Clinical Trials Registry (ChiCTR2300076236).

show abstract

Impact of chronic outward force on arterial responses of proximal and distal of long superficial femoral artery stent

Cited by 6 publications

References 29 publications

Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes

Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes

Preoperative Sizing to Lower In-Stent Restenosis in Peripheral Arterial Occlusive Disease

Safety and efficacy of drug-eluting stents versus heparin-bonded stents in treatment of femoropopliteal peripheral artery disease: study protocol for a multicentre, prospective randomised controlled trial in China (ELITE trial)

Contact Info

Product

Resources

About